Ira Winer, MD, PhD, associate professor, Division of Gynecologic Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, discusses the tolerability of ALKS 4230 plus pembrolizumab (Keytruda) in ovarian cancer. 

Findings from the ongoing phase 1/2 ARTISTRY-1 trial were presented during the 

The results demonstrated objective responses with the combination of ALKS 4230, an investigational engineered cytokine, and pembrolizumab in patients with heavily pretreated, platinum-resistant ovarian cancer. 

The ARTISTRY-1 regimen is intensive, but patients appeared to tolerate the combination well, says Winer. 

Videos

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer. 

Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer

Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.

Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.
 

Ira Winer, MD, PhD

Articles

Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer

Dr. Winer Discusses Immunotherapy in Gynecologic Malignancies